We review the representatives literatures on chronic osteomyelitis,sum up the new insights in recent years into diagnostic options and treatment regimens,analyze the advantages and disadvantages of various diagnostic ...We review the representatives literatures on chronic osteomyelitis,sum up the new insights in recent years into diagnostic options and treatment regimens,analyze the advantages and disadvantages of various diagnostic approaches and treatment strategies,and propose areas of interest to make current diagnostic and treatment strategies more specific.展开更多
目的探讨抗生素骨水泥联合Ilizarov技术个性化治疗长骨感染性骨缺损的方法和临床疗效。方法自2011年6月至2017年1月,我院应用Ilizarov技术个性化治疗股骨、胫骨、肱骨骨折术后感染性骨缺损21例,男14例,女7例;年龄18～65岁,平均37岁。其...目的探讨抗生素骨水泥联合Ilizarov技术个性化治疗长骨感染性骨缺损的方法和临床疗效。方法自2011年6月至2017年1月,我院应用Ilizarov技术个性化治疗股骨、胫骨、肱骨骨折术后感染性骨缺损21例,男14例,女7例;年龄18～65岁,平均37岁。其中胫骨骨缺损12例,清创后骨缺损范围平均7.2cm;股骨骨缺损7例,清创后骨缺损范围平均8.5cm;肱骨骨缺损2例,清创后骨缺损范围平均6cm。手术分两期进行:一期彻底清创,植入含敏感抗生素骨水泥,采用单边或环形外固定架固定,预留截骨延长的外固定架长度,控制感染;二期感染消灭后,根据Ilizarov技术进行截骨延长。结果所有患者术后随访12～24个月,平均18.5个月。外固定架固定时间9～21个月,平均17.2个月。外固定架指数(external fixation index,EFI)平均为2.38个月/cm。采用伊里扎洛夫方法研究与应用学会(association for the study and application of the method of Ilizarov,ASAMI)评价标准评价,骨性结果:优13例,良6例,中2例,优良率为90.5%;功能结果:优11例,良7例,中3例,优良率为85.7%。结论抗生素骨水泥联合Ilizarov技术可有效控制感染,纠正患肢畸形,重建肢体的功能,是治疗长骨感染性骨缺损的有效方法。展开更多
Polymethylmethacrylate(PMMA) bone cement technology has progressed from industrial Plexiglass administration in the 1950 s to the recent advent of nanoparticle additives. Additives have been trialed to address problem...Polymethylmethacrylate(PMMA) bone cement technology has progressed from industrial Plexiglass administration in the 1950 s to the recent advent of nanoparticle additives. Additives have been trialed to address problems with modern bone cements such as the loosening of prosthesis, high post-operative infection rates, and inflammatory reduction in interface integrity. This review aims to assess current additives used in PMMA bone cements and offer an insight regarding future directions for this biomaterial. Low index(< 15%) vitamin E and low index(< 5 g) antibiotic impregnated additives significantly address infection and inflammatory problems, with only modest reductions in mechanical strength. Chitosan(15% w/w PMMA) and silver(1% w/w PMMA) nanoparticles have strong antibacterial activity with no significant reduction in mechanical strength. Future work on PMMA bone cements should focus on trialing combinations of these additives as this may enhance favourable properties.展开更多
基金Supported by the National Natural Science Foundation of China(NO.81460339)Innovative Research Project For Graduate Students in Hainan Province(No.Hys2018-284)
文摘We review the representatives literatures on chronic osteomyelitis,sum up the new insights in recent years into diagnostic options and treatment regimens,analyze the advantages and disadvantages of various diagnostic approaches and treatment strategies,and propose areas of interest to make current diagnostic and treatment strategies more specific.
文摘目的探讨应用IIizarov外固定架骨搬运技术治疗胫骨骨折术后感染、骨缺损临床疗效。方法对60例胫骨骨折术后感染、骨缺损患者依据Ilizarov技术标准进行治疗。术后定期摄X线片复查,评估牵张成骨情况。结果 60例均获得随访,时间18~30个月。骨搬运完成时间2~7个月,骨搬运长度6~18 cm。患者未出现血管神经损伤等并发症。6例出现钉道反应,1例切口皮缘水肿,均经治疗后愈合;17例搬运后期出现对线不良,经调整骨搬运方向、少量植骨,均获对位对线骨性愈合。骨搬运完成后9个月,按Paley et al骨折愈合评分标准评价疗效:优45例,良6例,可8例,差1例。骨缺损断端骨愈合及牵张成骨区成骨愈合满意,软组织创面愈合满意,所有患肢长度恢复良好,与健侧对比无明显差异。结论采用Ilizarov外固定架骨搬运技术进行感染扩创、炎性病变切除、骨段搬运修复骨缺损,对胫骨术后感染的控制、肢体功能的重建具有确切的临床疗效。
文摘目的探讨抗生素骨水泥联合Ilizarov技术个性化治疗长骨感染性骨缺损的方法和临床疗效。方法自2011年6月至2017年1月,我院应用Ilizarov技术个性化治疗股骨、胫骨、肱骨骨折术后感染性骨缺损21例,男14例,女7例;年龄18～65岁,平均37岁。其中胫骨骨缺损12例,清创后骨缺损范围平均7.2cm;股骨骨缺损7例,清创后骨缺损范围平均8.5cm;肱骨骨缺损2例,清创后骨缺损范围平均6cm。手术分两期进行:一期彻底清创,植入含敏感抗生素骨水泥,采用单边或环形外固定架固定,预留截骨延长的外固定架长度,控制感染;二期感染消灭后,根据Ilizarov技术进行截骨延长。结果所有患者术后随访12～24个月,平均18.5个月。外固定架固定时间9～21个月,平均17.2个月。外固定架指数(external fixation index,EFI)平均为2.38个月/cm。采用伊里扎洛夫方法研究与应用学会(association for the study and application of the method of Ilizarov,ASAMI)评价标准评价,骨性结果:优13例,良6例,中2例,优良率为90.5%;功能结果:优11例,良7例,中3例,优良率为85.7%。结论抗生素骨水泥联合Ilizarov技术可有效控制感染,纠正患肢畸形,重建肢体的功能,是治疗长骨感染性骨缺损的有效方法。
文摘Polymethylmethacrylate(PMMA) bone cement technology has progressed from industrial Plexiglass administration in the 1950 s to the recent advent of nanoparticle additives. Additives have been trialed to address problems with modern bone cements such as the loosening of prosthesis, high post-operative infection rates, and inflammatory reduction in interface integrity. This review aims to assess current additives used in PMMA bone cements and offer an insight regarding future directions for this biomaterial. Low index(< 15%) vitamin E and low index(< 5 g) antibiotic impregnated additives significantly address infection and inflammatory problems, with only modest reductions in mechanical strength. Chitosan(15% w/w PMMA) and silver(1% w/w PMMA) nanoparticles have strong antibacterial activity with no significant reduction in mechanical strength. Future work on PMMA bone cements should focus on trialing combinations of these additives as this may enhance favourable properties.
